Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taminadenant - Novartis/Palobiofarma

Next Previous
X
Search
Drug Profile

Taminadenant - Novartis/Palobiofarma

Alternative Names: NIR 178; PBF-509

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palobiofarma
  • Developer Novartis; Palobiofarma
  • Class Amines; Antineoplastics; Antiparkinsonians; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Renal cell carcinoma
  • No development reported Attention-deficit hyperactivity disorder; Cancer; Lung cancer; Parkinson's disease; Triple negative breast cancer

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Canada (PO)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Hong Kong (PO)
  • 14 Feb 2023 Novartis Pharmaceuticals terminates a phase II clinical trial in Diffuse large B cell lymphoma (Combination therapy, Late-stage disease, Metastatic disease) in Singapore, Germany, Austria, France, USA, Argentina, Australia, Belgium, Czech Republic, Italy, Japan, Netherlands, Spain, Switzerland and Taiwan, based on sponsors decision (IV) (NCT03207867)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top